Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
暂无分享,去创建一个
Jennifer L. Bell | M. Landray | P. Horby | W. Lim | C. Brightling | C. Fegan | J. Emberson | J. Baillie | T. Jaki | A. Montgomery | K. Rowan | S. Faust | A. Ustianowski | N. Staplin | L. Chappell | E. Juszczak | M. Mafham | R. Haynes | B. Prudon | D. Chadwick | L. Linsell | E. Elmahi | C. Green | T. Felton | K. Rege | K. Jeffery | Christopher A Green | B. Prudon | Carole Green | -. R. C. Group | C. Green
[1] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[2] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[3] J. Riancho,et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia , 2020, medRxiv.
[4] C. Szabó,et al. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease , 2020, Critical Care.
[5] Andrea Gianatti,et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.
[6] P. Horby,et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review , 2020, BMJ.
[7] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[8] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[9] Xianbo Wu,et al. Viral dynamics in asymptomatic patients with COVID-19 , 2020, International Journal of Infectious Diseases.
[10] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[11] M. Dolhnikoff,et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[12] S. Antinori,et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy , 2020, medRxiv.
[13] Qiurong Ruan,et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[14] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[15] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[16] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[17] Eric H. Y. Lau,et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.
[18] W. Tu,et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[20] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[21] S. Zhang,et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.
[22] Louise Bowman,et al. The Magic of Randomization versus the Myth of Real-World Evidence. , 2020, The New England journal of medicine.
[23] Y. Hu,et al. On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.
[24] M. Zhou,et al. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[25] M. Zhou,et al. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[26] J. González-Martín,et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.
[27] J. Baillie,et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.
[28] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[29] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.
[30] J. Leonardi-Bee,et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2020, Critical care medicine.
[31] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[32] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[33] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[34] W. Lim,et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2019, Critical care medicine.
[35] Rajaa Al-Raddadi,et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.
[36] P. Horby,et al. Modernising epidemic science: enabling patient-centred research during epidemics , 2016, BMC Medicine.
[37] G. Guyatt,et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia , 2015, Annals of Internal Medicine.
[38] J. Baillie,et al. Influenza--time to target the host? , 2013, The New England journal of medicine.
[39] J. Sung,et al. Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza , 2009, The Journal of infectious diseases.
[40] Ali Danesh,et al. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.
[41] Yi Guan,et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.
[42] Paul Garner,et al. SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.
[43] V. Wong,et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.
[44] W. Lim,et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome , 2004, The Lancet.
[45] J. Sung,et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.
[46] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[47] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[48] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.